Point72 Asset Management L.P. Lowers Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Point72 Asset Management L.P. cut its stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 58.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 215,160 shares of the company's stock after selling 301,774 shares during the period. Point72 Asset Management L.P. owned about 0.35% of Health Catalyst worth $1,521,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in Health Catalyst by 21.7% in the 4th quarter. SG Americas Securities LLC now owns 27,382 shares of the company's stock worth $194,000 after buying an additional 4,874 shares during the last quarter. Inspire Investing LLC boosted its stake in shares of Health Catalyst by 14.2% in the 4th quarter. Inspire Investing LLC now owns 56,379 shares of the company's stock valued at $399,000 after purchasing an additional 7,019 shares in the last quarter. Dynamic Advisor Solutions LLC bought a new position in shares of Health Catalyst during the 4th quarter valued at $180,000. Stoneridge Investment Partners LLC purchased a new position in Health Catalyst in the 4th quarter worth $77,000. Finally, Legato Capital Management LLC raised its position in Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock worth $622,000 after purchasing an additional 3,171 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the sale, the chief operating officer now owns 216,250 shares of the company's stock, valued at approximately $977,450. The trade was a 7.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now directly owns 160,437 shares of the company's stock, valued at approximately $729,988.35. The trade was a 7.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,147 shares of company stock worth $182,284. 2.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HCAT shares. Piper Sandler reduced their price objective on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. Citigroup reduced their price target on Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a research report on Friday, April 25th. Royal Bank of Canada lowered their price objective on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Thursday, February 27th. KeyCorp dropped their price objective on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Finally, Stephens lowered their price target on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Health Catalyst Price Performance

Shares of Health Catalyst stock opened at $3.74 on Thursday. The business has a 50 day moving average of $4.11 and a 200 day moving average of $5.73. Health Catalyst, Inc. has a 52 week low of $3.56 and a 52 week high of $9.24. The company has a market cap of $260.31 million, a PE ratio of -2.77 and a beta of 1.56. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.